Mast Therapeutics Company Profile (NYSE:MSTX)

Notice: This company has been marked as potentially delisted and may not be actively trading.

About Mast Therapeutics (NYSE:MSTX)

Mast Therapeutics logoMast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSE:MSTX
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $0.12
  • 200 Day Moving Avg: $0.11
  • 52 Week Range: $0.07 - $0.71
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.76
  • P/E Growth: 0.00
Misc:
  • Average Volume: 5.10 million shs.
 

Frequently Asked Questions for Mast Therapeutics (NYSE:MSTX)

What is Mast Therapeutics' stock symbol?

Mast Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "MSTX."

How were Mast Therapeutics' earnings last quarter?

Mast Therapeutics Inc (NYSE:MSTX) issued its earnings results on Tuesday, August, 9th. The company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.01. View Mast Therapeutics' Earnings History.

Who are some of Mast Therapeutics' key competitors?

What is Mast Therapeutics' stock price today?

One share of Mast Therapeutics stock can currently be purchased for approximately $0.13.


MarketBeat Community Rating for Mast Therapeutics (NYSE MSTX)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  253
MarketBeat's community ratings are surveys of what our community members think about Mast Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mast Therapeutics (NYSE:MSTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A
Consensus Price Target History for Mast Therapeutics (NYSE:MSTX)
Price Target History for Mast Therapeutics (NYSE:MSTX)
Analysts' Ratings History for Mast Therapeutics (NYSE:MSTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/19/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
10/14/2016S&P Equity ResearchBoost Price Target$0.08 -> $0.09N/AView Rating Details
9/23/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
9/21/2016LaidlawDowngradeBuy -> NeutralN/AView Rating Details
9/21/2016Maxim GroupDowngradeBuy -> HoldN/AView Rating Details
8/1/2016Roth CapitalReiterated RatingBuy$2.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Mast Therapeutics (NYSE:MSTX)
Earnings by Quarter for Mast Therapeutics (NYSE:MSTX)
Earnings History by Quarter for Mast Therapeutics (NYSE MSTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016Q316($0.05)($0.04)ViewListenView Earnings Details
8/9/2016Q2($0.06)($0.05)ViewN/AView Earnings Details
5/6/2016Q116($0.06)($0.06)ViewN/AView Earnings Details
3/14/2016Q415($0.06)($0.06)ViewN/AView Earnings Details
11/12/2015Q315($0.06)($0.06)ViewListenView Earnings Details
8/12/2015($0.04)($0.06)ViewN/AView Earnings Details
8/12/2015Q215($0.04)($0.06)ViewListenView Earnings Details
5/11/2015Q1($0.06)($0.06)ViewN/AView Earnings Details
3/24/2015Q414($0.06)($0.05)ViewN/AView Earnings Details
10/31/2014Q314($0.06)($0.06)ViewN/AView Earnings Details
8/11/2014Q214($0.06)($0.06)ViewN/AView Earnings Details
5/5/2014Q114($0.07)($0.06)ViewN/AView Earnings Details
3/26/2014($0.07)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mast Therapeutics (NYSE:MSTX)
Current Year EPS Consensus Estimate: $-0.16 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS

Dividends

Dividend History for Mast Therapeutics (NYSE:MSTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Mast Therapeutics (NYSE:MSTX)
Insider Trades by Quarter for Mast Therapeutics (NYSE:MSTX)
Institutional Ownership by Quarter for Mast Therapeutics (NYSE:MSTX)
Insider Trades by Quarter for Mast Therapeutics (NYSE:MSTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/27/2015Brandi RobertsCFOBuy38,000$0.50$19,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Mast Therapeutics (NYSE:MSTX)
Latest Headlines for Mast Therapeutics (NYSE:MSTX)
Source:
DateHeadline
finance.yahoo.com logoMast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market
finance.yahoo.com - October 5 at 9:31 AM
finance.yahoo.com logoLeading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Mast Therapeutics Stockholders Vote "FOR" The Proposed Merger And Related Proposals
finance.yahoo.com - October 5 at 9:31 AM
finance.yahoo.com logoMast Reminds Stockholders To Vote For The Proposed Merger With Savara
finance.yahoo.com - October 5 at 9:31 AM
finance.yahoo.com logoMast Therapeutics Announces Possible Adjournment Of Special Stockholders Meeting To Solicit Additional Votes For Merger With Savara
finance.yahoo.com - October 5 at 9:31 AM
finance.yahoo.com logoMast Therapeutics Announces Adjournment Of Special Stockholders Meeting
finance.yahoo.com - October 5 at 9:31 AM
finance.yahoo.com logoMast Therapeutics And Savara Announce Anticipated Merger Exchange Ratio
finance.yahoo.com - October 5 at 9:31 AM
finance.yahoo.com logoSavara Announces Closing Of Merger With Mast Therapeutics
finance.yahoo.com - October 5 at 9:31 AM
prnewswire.com logoSavara Announces Closing Of Merger With Mast Therapeutics - PR Newswire (press release)
www.prnewswire.com - April 27 at 7:13 PM
streetinsider.com logoMast Therapeutics (MSTX) Says it May Adjourn Special Meeting to Solicit Additional Votes For Merger With Savara - StreetInsider.com
www.streetinsider.com - April 20 at 6:45 PM
biz.yahoo.com logoMAST THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi
biz.yahoo.com - March 28 at 6:26 PM
us.rd.yahoo.com logoMast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara
us.rd.yahoo.com - March 16 at 9:08 AM
us.rd.yahoo.com logoMast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
us.rd.yahoo.com - March 6 at 6:11 PM
biz.yahoo.com logoMAST THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 6 at 8:23 AM
biz.yahoo.com logoMAST THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 22 at 8:34 AM
biz.yahoo.com logoMAST THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princi
biz.yahoo.com - January 23 at 6:59 PM

Social

Chart

Mast Therapeutics (MSTX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.